Navigation Links
Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
Date:4/4/2013

CAMBRIDGE, Mass., April 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI). MM-121 is being evaluated in two additional NSCLC cohorts as well as Phase 2 studies for the treatment of advanced ovarian cancer, hormone-receptor positive breast cancer and HER2 negative breast cancer.

The primary objective of this 50 patient, single arm study was to determine the potential of MM-121, a novel signaling inhibitor targeting ErbB3, to modulate or reverse resistance to erlotinib, an EGFR targeted therapy, commonly used in the treatment of NSCLC, in patients who have acquired resistance to EGFR-TKI therapy.  The primary endpoint of this cohort was to obtain a 40 percent progression free survival rate at four months of treatment. Secondary endpoints included biomarker assessment of patients enrolled in the study.

A secondary objective of the study was to evaluate tissue samples from patient biopsies to assess whether the biomarker hypothesis behind MM-121 could be translated into a clinical setting. In order to conduct this analysis, pre-dose biopsies were required from each patient upon entering the study.

"These are data on the first of three NSCLC patient populations where we are studying the potential benefit of MM-121 in combination with erlotinib. A strong component of these studies is a focused translational program directed toward the identification of a biomarker profile for the combination in this difficult to treat cancer," said Akos Czibere , MD, PhD, S
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
2. Valeant Pharmaceuticals Provides Update to Recent Event
3. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
4. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
5. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
6. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
7. Valeant Pharmaceuticals Announces Private Exchange Offer
8. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
9. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
10. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
11. Pharmaceuticals - Scandinavia Industry Guide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Cardiologists at Beaumont ... the Midwest,s first commercial implant of a device recently ... with non-valvular atrial fibrillation. The Watchman Left Atrial Appendage ... blood-thinning warfarin medication to reduce the risk of stroke. ... rhythm disorder affecting more than 5 million Americans. Twenty ...
(Date:3/26/2015)... 2015 Over-the-counter healthcare costs can be ... a new survey of store brand over-the-counter products ... cold to diabetes, can offer significant savings for ... the Private Label Manufacturers Association, assembled a market ... those essential for treatment of pre-diabetes and diabetes. ...
(Date:3/26/2015)... March 26, 2015 Zimmer Holdings, Inc. (NYSE ... ® Advanced Bearing Technology with Vitamin E by ... published earlier this month reported that, at 96 million ... Advanced Bearing Technology featuring Vitamin E grafted highly crosslinked ... wear rate reduction of 95 percent, with no cracking, ...
Breaking Medicine Technology:Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Consumers can keep over-the-counter medicine affordable by using store brands 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 3
... SAN DIEGO, Aug. 4, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... for the quarter ended June 30, 2011. (Logo: ... for the second quarter of 2011 of $24.2 million, or ... as compared to a net loss for the second ...
... Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will release financial results for the second ... Monday, August 15, 2011 before the start of trading ...
Cached Medicine Technology:Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 2Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 3Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 4Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results 5Dehaier Medical to Report Second Quarter 2011 Financial Results on August 15 2
(Date:3/27/2015)... 2015 Ticket Down is a reputable source ... in Omaha, Nebraska on Friday, May 8th and Saturday, ... dates will be added in Omaha as Garth has done ... The Garth Brooks World Tour is continuing its run throughout ... Garth Brooks and Trisha Yearwood will bring their act to ...
(Date:3/27/2015)... Michigan (PRWEB) March 27, 2015 ... LiveToBeSober.org, along with former Detroit Lions wide receiver ... luncheon and educational presentation on substance abuse, treatment ... Among those who attended were pastors, ministers and ... leaders and other distinguished guests. , “Our ‘Fighting ...
(Date:3/27/2015)... According to Health Day , on March ... Syndrome (NAS) are causing alarm for Florida officials. Infants ... for a month of their lives- and can experience ... The condition is precipitated by drug use during pregnancy. ... employing medically assisted drug treatment) will also inflict NAS ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 GrassrootsHealth, an ... Protect Our Children (POC) NOW! vitamin D demonstration project ... University of South Carolina (MUSC), and will soon follow ... available at no cost to a minimum of 500 ... live within these two service areas. The project will ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Operatic contenders ... of greatness on April 17th. The universally acclaimed baritone ... the 9th annual Opera Idol at The Merion in ... competition, which has drawn aspiring opera singers from around ... showcases some of the finest young talent in the ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Opera Idol Competition At The Merion In Evanston 2
... chair to support efforts to address the rising ... in Maryland BALTIMORE, April 10 Richard H. ... General (2002-2006) and President of the non-profit Canyon ... elected Chairman of the Pharmaceutical Research and Manufacturers ...
... scientific article is cited by other articles is currently the ... measure: the number of unique downloads. , A recent ... that downloads are a good predictor of citations and ... in an editorial by Journal of Vision (JOV) ...
... 14-17, 2009, Underwriters Laboratories Inc.,s (UL) Primary Designated ... Manager Jola Wroblewska will present International Electrotechnical Committee ... (IECEE) CB Test Laboratories and National Certification Bodies ... promote common application of the guidelines prepared by ...
... April 10 Rheumatoid arthritis (RA) is a systemic ... defense system attacks the joints through the thin layer ... the joints. The most visible symptoms of RA are ... and feet. It can cause fatigue, fever, loss of ...
... eye physicians recommends , sport-specific eyewear to prevent devastating ... what started out as a routine basketball game his senior ... was a young basketball star who played years of hoops ... the eye by a teammate, Stephen ended up with a ...
... for skin appearance in 3 trials , , THURSDAY, April 9 ... to improve the healing of skin scars, according to three ... administered to their skin before wounding and again 24 hours ... the way through the skin of the upper inner arm ...
Cached Medicine News:Health News:National Health Experts to Announce Creation of Bipartisan Coalition to Fight Maryland's Growing Burden of Chronic Disease Tuesday at Inner Harbor 2Health News:UL Medical Experts to Provide Instruction on Guidance for Risk Management in IEC 60601-1:2005 at IECEE Workshop 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 3Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Medication May Improve Scar Healing 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
Medicine Products: